The Status and Prospects of Epigenetics in the Treatment of Lymphoma

Liu, Jiaxin; Li, Jianan; Wu, Hongyu; Li, Panpan

doi:10.3389/fonc.2022.874645

Cited by 11 publications

(6 citation statements)

References 185 publications

(200 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given its broad regulatory effect on various processes, epigenetics was recently classified as an important hallmark of carcinogenesis. As various epigenetic alterations were reported recently in HL cells ( 66 , 67 ), it is highly likely that systematic deciphering of the role of these non-mutational changes on the genetic sequence may improve understanding of the molecular mechanisms of the development, progression and aggressiveness of this cancer type.…”

Section: Aberrant Epigenetic Mechanisms In Hlmentioning

confidence: 99%

New molecular targets in Hodgkin and Reed-Sternberg cells

et al. 2023

View full text Add to dashboard Cite

Recent discoveries shed light on molecular mechanisms responsible for classical Hodgkin lymphoma (HL) development and progression, along with features of Hodgkin – Reed and Sternberg cells (HRS). Here, we summarize current knowledge on characteristic molecular alterations in HL, as well as existing targeted therapies and potential novel treatments for this disease. We discuss the importance of cluster of differentiation molecule 30 (CD30) and the programmed cell death-1 protein (PD-1) and ligands (PD-L1/2), and other molecules involved in immune modulation in HL. We highlight emerging evidence indicating that the altered function of SWI/SNF-type chromatin remodeling complexes, PRC2, and other epigenetic modifiers, contribute to variations in chromatin status, which are typical for HL. We postulate that despite of the existence of plentiful molecular data, the understanding of HL development remains incomplete. We therefore propose research directions involving analysis of reverse signaling in the PD-1/PD-L1 mechanism, chromatin remodeling, and epigenetics-related alterations, in order to identify HL features at the molecular level. Such attempts may lead to the identification of new molecular targets, and thus will likely substantially contribute to the future development of more effective targeted therapies.

show abstract

Section: Aberrant Epigenetic Mechanisms In Hlmentioning

confidence: 99%

New molecular targets in Hodgkin and Reed-Sternberg cells

et al. 2023

View full text Add to dashboard Cite

show abstract

“…These bioinformatics targets can be found by directly affecting regulatory regions of genes, such as in the methylome or DNA methylation information sets, or by altering histone proteins and related structures. 206 The methylome can be profiled experimentally by bisulfite sequencing, while the main technique for identifying histone alteration profiles is immunoprecipitation of these proteins.…”

Section: Personalized Epigenome Targeting In Nhlmentioning

confidence: 99%

Epigenetic targets in B- and T-cell lymphomas: latest developments

Ribeiro

Sánchez-Vinces

Mondragón

et al. 2023

Therapeutic Advances in Hematology

View full text Add to dashboard Cite

Non-Hodgkin’s lymphomas (NHLs) comprise a diverse group of diseases, either of mature B-cell or of T-cell derivation, characterized by heterogeneous molecular features and clinical manifestations. While most of the patients are responsive to standard chemotherapy, immunotherapy, radiation and/or stem cell transplantation, relapsed and/or refractory cases still have a dismal outcome. Deep sequencing analysis have pointed out that epigenetic dysregulations, including mutations in epigenetic enzymes, such as chromatin modifiers and DNA methyltransferases (DNMTs), are prevalent in both B- cell and T-cell lymphomas. Accordingly, over the past decade, a large number of epigenetic-modifying agents have been developed and introduced into the clinical management of these entities, and a few specific inhibitors have already been approved for clinical use. Here we summarize the main epigenetic alterations described in B- and T-NHL, that further supported the clinical development of a selected set of epidrugs in determined diseases, including inhibitors of DNMTs, histone deacetylases (HDACs), and extra-terminal domain proteins (bromodomain and extra-terminal motif; BETs). Finally, we highlight the most promising future directions of research in this area, explaining how bioinformatics approaches can help to identify new epigenetic targets in B- and T-cell lymphoid neoplasms.

show abstract

“…Understanding the genetic and epigenetic components of immune evasion is crucial. Studies on the modulation of epigenetics and immune checkpoints have shown an interaction between immune modulation and epigenetic alterations [14]. This review article provides a comprehensive summary of the latest research on the epigenetic modifications that can result in immune evasion and the development of T-cell malignancies.…”

Section: Introductionmentioning

confidence: 99%

Epigenetic Alterations That Are the Backbone of Immune Evasion in T-Cell Malignancies

Andreescu¹

2023

Preprint

View full text Add to dashboard Cite

Epigenetic alterations are heritable and enduring modifications in gene expression that play a pivotal role in immune evasion. These include alterations to noncoding RNA, DNA methylation, and histone modifications. DNA methylation plays a crucial role in normal cell growth and development but alterations in methylation patterns such as hypermethylation or hypomethylation can enable tumor and viral cells to evade host immune responses. Histone modifications can also inhibit immune responses by promoting the expression of genes involved in suppressing normal immune function. In the case of T-cell lymphoma, adult T-cell Lymphomas (ALT) also undergo immune evasion through the exceptional function of its accessory and regulatory genes. Epigenetic therapies are emerging as a promising adjunct to traditional immunotherapy and chemotherapy regimens. Clinical trials are currently investigating the use of epigenetic therapies in combination with immunotherapies and chemotherapies for more effective treatment of ATL and other cancers. This review highlights epigenetic alterations that are widely found in T cell malignancies.

show abstract

The Status and Prospects of Epigenetics in the Treatment of Lymphoma

Cited by 11 publications

References 185 publications

New molecular targets in Hodgkin and Reed-Sternberg cells

New molecular targets in Hodgkin and Reed-Sternberg cells

Epigenetic targets in B- and T-cell lymphomas: latest developments

Epigenetic Alterations That Are the Backbone of Immune Evasion in T-Cell Malignancies

Contact Info

Product

Resources

About